TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Katja Weisel | EHA 2018 | Turning the tide after relapse: managing relapsed MM

By Stephanie Hill

Share:

Featured:

Katja WeiselKatja Weisel

Jun 19, 2018


23rd Congress of the European Hematology Association, 14-17 June 2018, Stockholm, Sweden

Katja Weisel
University of Tübingen, Tübingen, DE

Interview topic: Turning the tide after relapse: managing relapsed MM

English

German

Turning the tide after relapse: managing relapsed MM